Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pain 2Breast Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pain, Postoperative 1Neuroma 1Lower Urinary Tract Symptoms 1Low Anterior Resection Syndrome 1Hereditary leiomyomatosis and renal cell cancer 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Chronic Pain 1Carcinoma, Renal Cell 1Agnosia 1

Interventions

Cisplatin 88Fluorouracil 71Paclitaxel 69Radiotherapy 63Oxaliplatin 55Irinotecan 37Docetaxel 36Carboplatin 36Leucovorin 34Capecitabine 28Radiation 25Surgical Procedures, Operative 22Drug Therapy 19pembrolizumab 18Cetuximab 15Bevacizumab 15Nivolumab 14tislelizumab 12camrelizumab 11Neoadjuvant Therapy 11Esophagectomy 11Chemoradiotherapy 11S 1 (combination) 10Albumin-Bound Paclitaxel 10nimotuzumab 9Trastuzumab 9durvalumab 8Radiotherapy, Intensity-Modulated 8Gefitinib 7Epirubicin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Esophageal Neoplasms × Botulinum Toxins, Type A × Clear all
NCT02965976 2023-02-16

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

Roswell Park Cancer Institute

Phase 2 Completed
33 enrolled 17 charts
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡